Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Osteoarthritis Cartilage. 2010 Sep 9;18(11):1509–1517. doi: 10.1016/j.joca.2010.08.014

Figure 5.

Figure 5

Effect of blocking p38 MAP kinase activation on blunt impact-induced ERK activation. At 24 hr post-impaction, tissue lysates from non-impacted controls (N. C.), from impacted (I) or annulus (A) cartilage. Experimental groups included control explants without any inhibitor treatments, and explantspre-treated with U0126 (U.), a MEK1/2/ERK1/2 inhibitor, or with SB202190 (SB.), a p38 MAP kinase pathway inhibitor. Lysate proteins were resolved by SDS-PAGE and blotted onto a nitrocellulose membranes. The membranes were probed with anti-total ERK (t-ERK1/2) or anti-phospho-ERK (p-ERK1/2) antibodies. In these studies, two sets of osteo-chondral explants were pre-treated with above inhibitors. They are designated as U.-1, SB.-1, U.-2, and SB.-2 on the blots, respectively.